the human IL-2R␣ gene. Each regulatory region appears to play a well-defined and complementary role. PRRI, located between nucleotides Ϫ276 and Ϫ244, contributes to the inducibility of the IL-2R␣ gene, whereas PRRII, located between nucleotides Ϫ137 and Ϫ64, is involved in basal promoter activity as well as in T-cell-specific expression (25) . PRRIII, located between nucleotides Ϫ3786 and Ϫ3701, is a specific IL-2-responsive enhancer playing a crucial role in the response to the IL-2/IL-2R autoregulatory loop which amplifies IL-2R␣ gene transcription in the late stage of T-cell activation (26, 32, 57) . The transcriptional activity of PRRI can be regulated by the viral protein Tax (transcription activator protein of human T-cell leukemia virus type 1), and the transcription factors NF-B and a serum response factor-related protein (2, 30, 35, 47) . Elf-1, a member of the Ets family of proteins specific for lymphoid tissue, and the nonhistone chromatin-associated protein, HMG-I(Y), regulate PRRII (25) . The transcriptional activity of PRRIII/IL-2rE is controlled by the functional interaction of Stat5, Ets-1, and Ets-2 in response to IL-2 stimulation (50) .
While the molecular mechanisms linking the CD28-mediated signal transduction pathways (8, 52, 64) and the transcriptional machinery have yet to be fully characterized, different CD28 response elements (CD28RE) have been delineated within the promoters of several cytokines including IL-2 (9, 16, 62) , IL-4 (38), IL-6 (10), IL-8 (65) IL-3, granulocyte-macrophage colony-stimulating factor and gamma interferon (17) . Despite sequence similarity, at least two functionally distinct classes of CD28RE exist that coincide with differences in their NF-B binding activity (10) , and all characterized CD28RE to date were associated with this family of transcription factors. For instance, the well-characterized CD28-responsive complex (CD28RC) that binds to the IL-2 promoter contains at least three members of the Rel/NF-B family, c-Rel, RelA(p65), and p50 (19, 31) , but also unrelated transcription factors such as NF-ATp (39) and AP-1 proteins (54) . Furthermore, the CD28 costimulatory signals can activates the cyclic AMP-responsive element binding proteins CREB/ATF-1 in T lymphocytes (24) and ATF-1/CREB2 in Jurkat leukemia T cells (5) .
In marked contrast, none of the previously identified regulatory regions responds to CD28 signaling in gene reporter assays although CD28 stimulation strongly amplifies IL-2R␣ gene transcription (7) . To understand how CD28 can up-regulate IL-2R␣ gene expression at the transcriptional level, we used an experimental strategy combining DNase I hypersensitivity analysis, in vivo footprinting, transient reporter gene assays, and electrophoretic mobility shift assays (EMSAs) to identify this important missing element. In the present study, we identified a novel inducible regulatory region, hereafter designated positive regulatory region IV (PRRIV). This region, located 8.5 kb upstream of the IL-2R␣ gene, responds efficiently to CD28 stimulation and fulfills the requirements for a bona fide CD28 responsive enhancer (CD28rE). IL-2R␣ PRRIV matches a T-cell receptor (TCR)-CD3-and/or CD28-inducible DNase I-hypersensitive (DH) site. Moreover, the inducible transcriptional activity of PRRIV is mediated by the functional cooperation between CREB/ATF and Jun/AP-1 family proteins and enhanced by CD28 costimulatory signals.
(This work partially fulfills the requirement for the doctoral thesis of J.-H. Yeh at the Université de la Méditerranée.) pcDNA3-CREB (S133A) (49) , were gifts of P. G. Quinn (Pennsylvania State University, Hershey, Pa.).
Transient-transfection and reporter gene assays. Jurkat T cells were transfected with 7.5 to 30 g of the indicated plasmids at 250 V and 960 F in a Bio-Rad (Hercules, Calif.) Gene Pulser. For COS 1 cells, transfections were performed using FuGENE 6 transfection reagent (Roche). Transfected cells were then activated with different stimuli as indicated in figure legends. Cells were harvested 16 h later for CAT assays and 6 h later for luciferase assays. Cell lysis and chloramphenicol acetyltransferase (CAT) assays were performed with the CAT enzyme-linked immunosorbent assay kit (Boehringer Mannheim), as specified by the manufacturer, with 50 g of cell extracts. Luciferase assays were performed with the dual-luciferase reporter assay system (Promega) with 15 g of cell extracts, and luciferase activity was measured with a Dynex MLX microplate luminometer. In Fig. 2 to 4 and 7, histogram and error bars represent the mean of at least 3 and up to 21 independent measurements, and the standard error of the mean, respectively.
Reverse transcription-PCR (RT-PCR) and FACScan analysis. CD28-deficient Jurkat JF3 T cells were transfected with 20 g of pH␤APr-1-CD28 wt (neo) or pH␤APr-1-CD28 ⌬30 (neo). Cells were harvested and washed 24 h after transfection, and RNA was extracted using Trizol. A 2-g portion of total RNA was used for cDNA synthesis by random priming. PCR was used with primers 5Ј-hCD28 (GTGAAATGCTGCAGTCAGGA) and 3Ј-hCD28 (ACCTGAAGCTG CTGGGAGTA). All cell cultures were harvested 24 h after transfection and incubated at 4°C for 45 min with monoclonal antibodies (MAbs) in the dark. The cells were analyzed by flow cytometry (FACScan; Beckton Dickinson) using the CELLQuest software (Beckton Dickinson). The MAb used in our study was anti-human CD28 (phycoerythrin [PE]-conjugated clone CD28.2) from Immunotech (Marseille, France).
In vivo footprint analysis. Genomic footprint analyses were performed as previously described (2) by the dimethylsulfate-ligation-mediated PCR (DMS/ LM-PCR) method using in vitro and in vivo methylated genomic DNA purified from human primary T cells. The following oligonucleotide primers were used for the coding strand: primer 1, TCACTAGCACTGACTAGGC (Ϫ8408 to Ϫ8389; T m , 60°C); primer 2, GGCAAGCACTGTGCTGAGAATGTTG (Ϫ8444 to Ϫ8419; T m , 63°C); and primer 3, TGCTGAGAATGTTGCATGTCTCTGC CGCT (Ϫ8459 to Ϫ8430; T m , 66°C); the following were used for the noncoding strand: primer 1, CAATGCTTAACGACTGAGC (Ϫ8804 to Ϫ8785; T m , 58°C); primer 2, GCTAAGTACTGAACTCAGCACTAGG (Ϫ8774 to Ϫ8750; T m , 61°C); and primer 3, CTCAGCACTAGGAATAAGAAGGCGACCTA (Ϫ8761 to Ϫ8733; T m 64°C).
EMSAs and Western blot analyses. Nuclear extracts of Jurkat JH6.2 T cells and purified T lymphocytes and EMSAs were performed as previously described (13) . Synthetic oligonucleotide probes were end labeled with [␥-
32 P]ATP. The following probes were used: wt CRE/TRE, ACACCACTCCTGACGAATTAT GTGAG; mCRE/TRE, ACACCACTCCTCTAGATTATGTGAG (the CRE/ tetradecanoyl phorbol acetate responsive element (TRE) motif is underlined, and the substituted nucleotides to disrupt the consensus are in boldface); highaffinity CREa (a motif derived from the promoter region of the cyclin A gene [48] ), CGCCTTGAATGACGTCAAGGC. Supershift and blocking assays of PRRIV CRE/TRE binding proteins were performed by incubating nuclear extract for 10 min on ice with different antibodies before the addition of 32 P-labeled probe. Anti-c-Jun/AP-1 (D), anti-c-Fos (6-2H-2F), anti-ATF-1 (25C10G), anti-CREB-1 (X-12), anti-ATF-1 (C41-5.1), and anti-ATF-2 (C-19) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif.). Anti-phospho-CREB was purchased from UBI. In competition experiments, unlabeled oligonucleotides were incubated for 15 min with nuclear extracts at 4°C before the addition of 32 P-labeled probe. For Western blots, 5 g of denatured nuclear extract was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10% polyacrylamide). Proteins were transferred to Immobilon-P membrane (Sigma), and phospho-CREB was detected with a 1/1,000 dilution of anti-phospho-CREB (Ser133) antibody (New England Biolabs) by using the enhanced chemiluminescence system (Amersham Life Science) with horseradish peroxidase-coupled goat anti-rabbit antibodies (Jackson ImmunoResearch Laboratories).
Chromatin immunoprecipitation (ChIP) assays. Chromatin from unstimulated or stimulated (20 h with CD3 plus CD28) human primary T cells was extracted and immunoprecipitated using the chromatin immunoprecipitation ChIP assay kit (Upstate Biotechnology, Inc.) as recommended by the manufacturer. The purified chromatin was immunoprecipitated using 10 g of anti-CREB or CBP (UBI); 15 g of anti-phospho-CREB (UBI); 10 g of anti-c-Jun/ AP-1, c-Fos/AP-1, ATF-2, or Ets1/2 (Santa Cruz); and 5 l of rabbit nonimmune serum. The input fraction corresponded to 0.1 and 0.01% of the chromatin solution before immunoprecipitation. Following DNA purification, the presence of selected DNA sequences was assessed by PCR. Fifteen cycles were performed with the first primer set in 50 l with 2 l of immunoprecipitated material. Then, using 2 l of the first PCR product, 25 additional cycles of PCR were performed with the CRE/TRE 3Ј primer set and 1 Ci of [␣-
32 P]dCTP. The PCR products were resolved in 8% acrylamide gels. A twofold dilution series was typically used for the first PCR amplification. The primers used were as follows: PRRIV 5Ј (5Ј-CTCCAGAGAGCTACAAGGCAGT-3Ј) and PRRIV 3Ј (5Ј-GTTGTGAA ACACCCACACTCAC-3Ј) (first PCR, 141-bp product); CRE/TRE 3Ј (5Ј-CTC ACATAATTCGTCAGGAGTGGTGT-3Ј) (second PCR, 125-bp product); PRRIII 5Ј (5Ј-TTCACCCCACTGTACGTC-3Ј) and PRRIII 3Ј (5Ј-GTCAACA GTGCAAGCTGAGTCT-3Ј) (first PCR, 173-bp product); and PRRIII 5Ј-2 (5Ј-TAAGGGAAGGCAGTCTAGGTCA-3Ј) (second PCR, 133-bp product).
RESULTS
Identification of PRRIV, a new positive regulatory region in the human IL-2R␣ gene. To further investigate the organization of the human IL-2R␣ chain locus, we analyzed the chromatin structure accessibility of this gene using DNase I hypersensitivity analysis (67) in human primary T cells. The probe shown in Fig. 1B labeled the original genomic DNA restriction fragment in addition to the subbands created by the cutting of DNase I at the hypersensitivity sites (Fig. 1A) . In human primary resting T cells, using high concentrations of DNase I, four weak sites of hypersensitivity were hardly detected. After stimulation via either TCR-CD3 or CD28, the chromatin structure appeared more sensitive to the nuclease since DH sites 1, 2, 3, and 4 were significantly reinforced. The potent mitogenic anti-CD3 and anti-CD28 combination resulted in a clear activation of the four sites and more particularly of DH site 4. DH sites 1, 2, 3, and 4 were located at kb Ϫ8.5, Ϫ6, Ϫ5, and Ϫ4.3 (Fig.  1B) , respectively, relative to the major transcription initiation site (14) . We excluded the possibility that the difference in DNase cleavage reflected differences in enzymatic activity in the different cell samples rather than an increased accessibility by analyzing the DNase I cleavage pattern of the IL-2R␣ gene proximal promoter-enhancer region. No significant differences were observed when the same DNA preparations were used (data not shown).
On the basis of these results, the corresponding region was screened for putative regulatory elements by transient-transfection assays. For this purpose, a series of fragments derived from a 9-kb fragment between nucleotides Ϫ8942 and ϩ110 were inserted upstream of the simian virus 40 (SV40) heterologous minimal promoter inserted either in the CAT reporter gene vector pTK3 or in the luciferase gene reporter vector pGL3. The transcriptional activity of these constructs was tested in the Jurkat JH6.2 T-cell line. These assays revealed that a BcII-SphI 207-nucleotide fragment, overlying DH site 4, conferred a positive transcriptional activity in response to PMA plus ionomycin that was much stronger than the activity conferred by a EcoRI-BamHI 2301-nucleotide fragment containing both DH sites 4 and 3, whereas the fragments containing DH sites 1 and 2 failed to respond (Fig. 1C) . To exclude the possibility of aberrant function revealed by the heterologous pTK3 CAT construct, the activity was also tested for the endogenous promoter region. As previously reported (14) , the proximal promoter-enhancer region containing PRRI plus PRRII failed to respond to PMA plus ionomycin (Fig. 1C , 481.IIR) whereas only a 3.5-fold induction was observed with the fragment from Ϫ8942 to ϩ100 that included the four DH sites (Fig. 1C, 8942 .IIR). Insertion of the BcII-SphI 207-nucleotide fragment upstream of the proximal promoter-enhancer region significantly increased CAT induction (Fig. 1C, 481 .IIR/ BcS). These results suggested the presence of some repressor sequences between the distal BcII-SphI 207-nucleotide fragment and the proximal promoter-enhancer region which were not further investigated. Furthermore, we have previously reported that a DNA fragment containing PRRIII does not respond to PMA plus ionomycin (32) . Sequence analysis using the NIX package software (http://www.hgmp.mrc.ac.uk) confirmed that no significant open reading frame was present between this upstream putative enhancer and the previously characterized IL-2R␣ PRRIII/IL-2rE (reference (32) and data not shown).
Collectively, our results strongly suggested that the BcIISphI 207-bp fragment is a novel positive cis-acting regulatory region in the 5Ј-flanking region of the human IL-2R␣ gene. It was designated PRRIV.
PRRIV can respond to TCR-CD3 and/or CD28 stimulatory signals. Since TCR-CD3-CD28 costimulation potently up-regulates the transcription of the human IL-2R␣ gene (7), we further investigated by transient transfection whether anti-CD3 and anti-CD28 activate the transcriptional activity of PRRIV in its endogenous context or in the heterologous pGL3/PRRIV construct. As illustrated in Fig. 2A , PRRIV inserted upstream of the IL-2R␣ proximal promoter-enhancer region responded to various stimuli that mimicked TCR-CD3 and CD28 engagement. When Jurkat T cells were treated with a combination of anti-CD3 and anti-CD28, the 481.IIR construct was hardly activated whereas the transcriptional activity of 481.IIR/PRRIV was strongly increased ( Fig. 2A) . Interestingly, the CAT assay revealed that anti-CD28 248 alone stimulated the transcriptional activity of PRRIV, which was additive to the transcriptional effect of anti-CD3 289 alone. This observation led us to postulate that PRRIV can respond to signal 2 (costimulatory signal) alone without signal 1 (TCR-CD3 signal).
To exclude the effect of downstream signals from the TCR-CD3 complex, we used the CD28 MAb BW828 (56) which can induce resting human T-cell proliferation and cytokine synthesis without TCR-CD3 engagement. BW828 induced the transcriptional activity of PRRIV as effectively as did CD28 MAb 248 (Fig. 2B) . Insertion of PRRIV upstream of the SV40 promoter led to a 90-fold increase of luciferase activity compared to pGL3 in response to the CD3-CD28 costimulation.
Collectively, our results strongly suggested that PRRIV is a CD28-responsive enhancer (CD28rE) in the human IL-2R␣ gene.
CD28 can specifically induce PRRIV transcriptional activity. To demonstrate that PRRIV can specifically respond to CD28 downstream signals, we used the CD28-deficient mutant Jurkat T-cell clone, JF3. As the JH6.2 subclone, JF3 was selected by limiting dilution of Jurkat JA3.52 T cells (43) . We used RT-PCR to control for the lack of CD28 expression in the JF3 subclone. As expected, no CD28 mRNA was detected in JF3 T cells (Fig. 3A) . Fluorescence-activated cell sorter FACS analysis for CD28 expression confirmed the absence of protein at the cell surface (Fig. 3B) . As a control, the Jurkat JH6.2 T cells expressed high levels of CD28 mRNA (Fig. 3A) and cell surface proteins (data not shown).
JF3 cells were transfected with pGL3/PRRIV and then treated with anti-CD3 and anti-CD28, alone or in combination. TCR-CD3 stimulation induced the activation of pGL3/PRRIV with a slightly lower efficiency than in Jurkat JH6.2 T cells (Fig.  3C) . In sharp contrast, PRRIV failed to respond to anti-CD28 in JF3 cells, as expected for a bona fide CD28rE. In agreement, no further stimulatory effect was found in JF3 cells treated with both CD3 and CD28 MAbs.
To confirm the specificity of CD28 action on PRRIV/ CD28rE, JF3 T cells were transiently cotransfected with pGL3/ PRRIV and a wild-type CD28 cDNA expression vector or the truncated form CD28⌬30 (44) . This nonfunctional form lacks almost all signal transduction motifs contained in the CD28 cytoplasmic domain. RT-PCR (Fig. 3A) and FACS analysis (Fig. 3B) confirmed reconstitution of CD28 wt and ⌬30 expression. Cell surface expression of CD28 ⌬30 was even more efficient than for CD28 wt form (Fig. 3B, 17% CD28 wt ϩ versus up to 90% CD28 ⌬30 ϩ ). Under these conditions, the transcriptional activity of PRRIV/CD28rE was efficiently restored by cotransfection with CD28 full-length cDNA (Fig.  3D) . In contrast, cotransfection with the truncated form CD28⌬30 failed to activate PRRIV/CD28rE. 
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The CD28-deficient JF3 T-cell clone allowed a direct demonstration that CD28 downstream signals alone are sufficient to trigger PRRIV transcriptional activity. Taken together, these data demonstrated that the human PRRIV within IL-2R␣ locus corresponds to a new CD28-responsive enhancer.
A CRE/TRE regulatory element within PRRIV is essential for the response to TCR-CD3 and CD28 signaling. Sequence analysis using the Transcription Element Search Software (TESS [http://www.cbil.upenn.edu/tess]) revealed several putative binding site for known transcription factors which play a major role during T-cell activation, such as NFAT, AP-1, and CREB/ATF family proteins within the DNA sequence of human PRRIV/CD28rE (Fig. 4A) . DMS/LM-PCR genomic footprint experiments (2) performed with human primary T cells gave evidence that the CRE/TRE was the only site among the putative regulatory elements significantly modified in response to CD3-CD28 costimulation on the coding strand whereas no clear occupancy was detected on the noncoding strand (Fig.  4B ). This site might correspond to a CRE or TRE. Since several reports have shown that CD28 can specifically activate the transcriptional activity of CREB/ATF and AP-1 family proteins (5, 24, 29, 60), we disrupted this CRE/TRE site into the pGL3/PRRIV construct (Fig. 5A ) to analyze its involvement in the PRRIV/CD28rE response to CD28 in JH6.2 cells and CD28-deficient Jurkat JF3 T-cell clone. In JH6.2 T cells, disruption of the CRE/TRE motif almost completely abolished the transcriptional activity of PRRIV/CD28rE in response to PMA plus ionomycin (data not shown), CD3, and CD28 stimulation (Fig. 5B) . CD28 specificity was further confirmed by cotransfection of wt CRE/TRE and mutated (mCRE/TRE) reporter constructs in JF3 cells. Expression of wt CD28 restored the transcriptional activity of wt PRRIV/CD28rE, whereas the mutated CRE/TRE failed to respond to CD28 signals (data not shown). Hence, the CRE/TRE motif within the PRRIV/CD28rE plays a crucial role in the transcriptional activity of this enhancer in response to TCR-CD3 and CD28 signaling.
Identification of transcription factors that bind in vitro to the CRE/TRE motif within the PRRIV/CD28rE in human primary T cells. EMSAs performed with a specific radiolabeled double-stranded oligonucleotidic probe identified nuclear factors bound to the functional PRRIV CRE/TRE motif and 
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NOVEL CD28-RESPONSIVE ENHANCER IN THE IL-2R␣ LOCUSnuclear extracts from unstimulated and TCR-CD3-and/or CD28-stimulated human primary T cells. Since factors present in the fetal bovine serum used in the cell culture medium might activate the CREB/ATF family proteins (4, 23), we cultured the human primary T cells in serum-free medium. EMSAs performed with the PRRIV CRE/TRE-specific probe revealed several protein-DNA complexes (Fig. 6A) . The weak constitutive complex C1 was strongly increased after stimulation by anti-CD3 alone or in combination with anti-CD28. The inducible complexe C2 was present at least 4 days after CD3-CD28 costimulation but was only transiently detected after 16 h in response to anti-CD3 alone (Fig. 6A , compare lanes 3 to 6 with lanes 8 to 11). Western blotting analysis performed with the same nuclear extracts revealed that anti-CD3 alone triggered a more transient phosphorylation of CREB-1 than did the TCR-CD3-CD28 combination, paralleling the detection of complex C2 under both conditions (Fig. 6A , compare the lower and upper panels). Competition assays with unlabeled doublestranded oligonucleotides evidenced that an excess of wt CRE/ TRE and CREa abolished the constitutive complex C1 and the inducible complex C2 (Fig. 6B , compare lane 1 with lanes 2 and 4 and lane 5 with lanes 6 and 8). In contrast, the mCRE/ TRE competitor did affect complexes C1 and C2 (Fig. 6B,  lanes 3 and 7) . Taken together, these data demonstrate that the protein-DNA complex C1 and C2 are specific for the PRRIV CRE/TRE motif in human primary T cells. CD28 activates CREB/ATF family proteins in T lymphocytes (5, 24) , and these transcription factors can bind the CRE motif as either homodimers or heterodimers with other CREB/ ATF family members or with members of the AP-1 transcription factor family (22, 46) . We hypothesized that the protein-DNA complexes C1 and C2 contained some of these proteins, and supershift experiments were performed with a panel of antisera recognizing CREB/ATF and AP-1 family factors. Anti-ATF-1, which recognizes ATF-1 p35, CREB-1 p43, and CREM, efficiently supershifted the constitutive complex C1 (Fig. 6C, compare lanes 1 and 4 with lanes 9 and 12) . This complex was also partially supershifted in unstimulated nuclear extracts (compare lane 1 with lanes 5 and 6) and completely abolished in CD3-CD28-stimulated extracts in the presence of anti-phospho-CREB and anti-CREB-1 (compare lane 9 with lanes 13 and 14) . Anti-c-Jun, which recognizes c-Jun, Jun B, and Jun D, supershifted the inducible complex C2 (compare lane 9 with lane 10). Anti-c-Fos, which recognizes c-Fos, Fos B, Fra-1, Fra-2, anti-ATF-1, and anti-ATF-2 sera, did not affect the formation of the CRE/TRE-specific protein-DNA complexes C1 and C2 (compare lanes 1, 3, 7, and 8 with lanes 9, 11, 15, and 16). Taken together, these data showed that the constitutive complex C1 bound specifically to the CRE/ TRE motif within PRRIV/CD28rE in human primary T cells contained at least CREB-1 p43 and that the TCR/CD3-and/or CD28-inducible complex C2 contained Jun/AP-1 family proteins.
Specific binding of CREB and AP-1 to PRRIV in vivo.
To reconcile the specific binding of CREB and AP-1 to PRRIV in vitro, we used ChIP assays (Fig. 7) . The ChIP technique can establish whether a known transcription factor truly binds in the vicinity of a known regulatory element in living cells (45) . We prepared resting and CD3-CD28-stimulated human primary T cells and then cross-linked their chromatin before subjecting them to immunoprecipitation with various antisera. The precipitated chromatin DNA was then purified and subjected to PCR analysis with specific DNA primers bracketing PRRIV or PRRIII. ChIP assays using anti-CREB antibody showed that CREB constitutively bound to PRRIV, as shown above in vitro. PRRIV-specific PCR products were generated using phospho-CREB, c-Jun/AP-1, c-Fos, and CBP antibodies only from activated T-cell but not resting T-cell chromatin samples in vivo (Fig. 7A) . After T-cell activation, AP-1 apparently cooperated with phosphorylated CREB and CBP to bind to PRRIV. In agreement with EMSAs, ATF-2 was not bound in vivo to PRRIV in primary T cells, like the irrelevant Ets1/2 (Fig. 7A) . Conversely, control experiments showed that DNAprotein complexes from CD3-CD28-stimulated primary T cells contained Ets1/2 binding to the PRRIII target sequence, as expected from our previous observations (50), but did not contain CREB (Fig. 7B) . Taken together, these results demonstrate that in human resting T cells, CREB constitutively binds to the genomic region containing PRRIV and that T-cell activation triggers the binding of Ser 133 -phosphorylated CREB with its coactivator CBP and with inducible AP-1 family factors. PRRIV/CD28rE. We next investigated the role of CREB-1, ATF-1, and the members of Jun/AP-1 family in transactivating PRRIV/CD28rE, using cotransfection experiments in COS-1 cells. As shown in Fig. 8A , CREB-1, ATF-1, c-Jun, and JunB efficiently transactivated pGL3/PRRIV whereas JunD had a much weaker effect. The disruption of the crucial CRE/TRE motif within PRRIV/CD28rE almost completely abolished these transactivation effects, confirming the DNA specificity of the action on PRRIV/CD28rE.
Exogenous expression of CREB/ATF and AP-1 family members in COS cells induces synergistic transactivation of
Since phosphorylation of CREB at Ser 133 is required for its transcriptional activity but not for its DNA binding ability (37, 55) , a CREB dominant negative expression vector containing an alanine substitution at Ser 133 (CREB DN) (49) 
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scriptional activity of pGL3/PRRIV induced by CREB-1 and significantly reduced the effects of ATF-1 and c-Jun (Fig. 8B) . Combined cotransfection of CREB-1, ATF-1, c-Jun, JunB, and JunD expression vectors and the PRRIV/CD28rE luciferase reporter plasmid construct showed a higher activity and synergy between ATF-1 and c-Jun (Fig. 7C) . The ATF-1/c-Jun combination induced a nearly eightfold-higher transactivation of PRRIV/CD28rE compared to other tested expression vectors.
Taken together, these data strongly suggest a functional cooperativity between the CREB/ATF family and AP-1 family in the transactivation of PRRIV/CD28rE.
DISCUSSION
In this work, we have identified and characterized an inducible DNase I HS site, DH site 4, located 5Ј of the human IL-2R␣ gene. Several arguments support the hypothesis that DH site 4 functions as a distal IL-2R␣ enhancer in vivo, cooperating with the previously characterized IL-2R␣ promoter and regulatory regions to enable optimal TCR-CD3 and CD28 T-cell-specific expression of IL-2R␣. First, the previously char- acterized promoter and regulatory regions are clearly insufficient to support high-level and CD28-specific transcription of a linked reporter gene (2, 14, 25, 26, 32, 57, 58) , and thus distal regulatory regions must be implicated. Second, DH site 4 is contained in a TCR-CD3 and CD28-responsive DNA fragment (PRRIV) of the IL-2R␣ gene. Third, the inducible reinforcement of DH site 4 mirrors the features of endogenous IL-2R␣ transcription as well as the properties of the PRRIV enhancer in transient-transfection assays. Fourth, the PRRIV enhancer corresponds to a new bona fide CD28-responsive enhancer and contains a functional CRE/TRE motif with several characteristics similar to but distinct from those of the previously reported CD28RE (10, 16, 62) .
In the early stage of T-cell activation, CD28 plays a critical role in amplifying the downstream signals of TCR-CD3, but later, absence of the CD28 signal leads to T-cell anergy or triggers apoptosis (52) . Interestingly, we observed that anti-CD28 MAbs alone are sufficient to induce the transcriptional activity of PRRIV/CD28rE in transient-transfection assays. This new enhancer might offer useful tool to facilitate the analysis of CD28 signaling in absence of TCR-CD3 engagement.
Efficient production of IL-2 and expression of IL-2R␣ by T cells are known to depend on the synergistic activation of T-cell antigen receptor and CD28 molecules on T cells. Several reports have also evidenced that CD28 signal transduction increases the transcriptional activity of the IL-2, IL-4, IL-6, IL-8 (65), IL-3, granulocyte-macrophage colony-stimulating factor, and gamma interferon proximal promoter/enhancers (9, 10, 16, 17, 38, 62) . It has been demonstrated that the costimulatory signal acts through B-like elements called CD28RE within the proximal promoter-enhancer regions of these important immunoregulatory genes. Taken together, these observations suggest that CD28-mediated gene expression is sustained by a synergistic cooperation between several transcriptional factors belonging to unrelated families, such as NF-B, AP-1, NF-AT, and CREB/ATF. Two different classes of CD28RE exist that differ in their NF-B binding activity despite sequence similarity (10) . The pivotal role played by Rel/NF-B proteins in CD28 responsiveness has been confirmed for many important immunoregulatory genes (18) and can be in part credited to their presence in the inducible CD28RC. The PRRIV/CD28rE identified in our study differs markedly from the previously characterized CD28 response element since it presents no sequence similarity to known CD28RE. Furthermore, its CD28 responsiveness depends on a crucial CRE/TRE motif, and no members of the Rel/NF-B family were bound in vitro to this regulatory element. In addition, PRRIV/CD28rE can be activated by CD28 stimulation alone whereas all other CD28RE required additional signals provided by CD3-TCR or mitogenic drugs. This new core enhancer hence defines a distinct class of CD28RE.
In agreement with the identification of CREB/ATF and AP-1 family members bound to the IL-2R␣ CRE/TRE site in primary and tumoral T cells, a previous report has established that CD28 responsiveness is conferred by a composite element including the CD28RE and the adjacent NF-IL-2B AP-1 sites in the promoter region of the human IL-2 gene (54). The CD28 costimulatory signals can activate CREB/ATF-1 in primary T lymphocytes (24) , and the coordinate transactivation of the IL-2 CD28RE apparently involves cross talk of c-Rel and ATF-1/CREB2 in Jurkat T cells (5) . Our results suggest that CREB, ATF-1, c-Jun, Jun B, and Jun D are involved in the transactivation of CRE/TRE on the basis of transient-overexpression experiments. This conclusion is strongly reinforced by the repressor effect of the CREB dominant negative form that binds to CREs but has no transcriptional activity. Furthermore, the ChIP assays have clearly established that T-cell activation triggers the binding of phospho-CREB with its coactivator CREB binding protein (CBP) and with inducible AP-1 family factors to the genomic region containing PRRIV. Therefore, our results clearly point to a pivotal role for the CREB/ATF and AP-1 family proteins in the regulation of PRRIV transcriptional activity in response to TCR and/or CD28 that may require their coordinated interactions.
The importance of Ser 133 phosphorylation is demonstrated by the phenotype of transgenic mice expressing the dominant negative CREB (alanine-133-CREB) (3, 59) , which are deficient for thymocyte proliferation and IL-2 production (3). In contrast to the canonical model of CREB/ATF activation (15), we observed that phospho-Ser 133 CREB and phospho-Ser 63 ATF-1 can bind to PRRIV CRE/TRE site in resting primary T cells. Experiments performed with serum-free medium excluded the possibility that serum factors accounted for this discrepancy. However, the constitutive phosphorylation of CREB at Ser 133 might be triggered by stress kinases during primary T-cell purification. In line with the constitutive detection of CREB/ATF proteins bound to CRE/TRE, CREB is constitutively targeted to the nucleus via a nuclear localization sequence within the C-terminal basic region (20, 63) . Also, DNA binding studies of recombinant CREB indicate that Ser 133 phosphorylation has no effect on CREB binding to its cognate binding site CRE (21) but plays a crucial role in activation of CREB transcription potential. CRE/TRE within PRRIV/CD28rE contains a single TGACG motif, and Ser 133 phosphorylation increased CREB binding to such low-affinity CRE sites (42) . The increase of phospho-CREB expression after stimulation detected by both Western blotting and ChIP assays suggests that additional phosphorylation is required to fully activate CREB transcriptional activity. Although CREB/ ATF family proteins constitutively bind to the CRE/TRE site, our observations are in agreement with a critical role in IL-2R␣ gene expression in response to CD28 and/or TCR.
We cannot exclude at this stage the involvement of other transcription factors in PRRIV/CD28rE transcriptional regulation since it contains two NF-AT sites and one AP-1 site besides the CRE/TRE motif. However, site-directed mutagenesis and reconstitution experiments in CD28-deficient Jurkat JF3 T cells have firmly established the crucial role played by this regulatory element in CD28 responsiveness. The CD28 signal transduction pathways involve a complex network of several protein kinases and adapters that ultimately results in T-cell proliferation, cytokine secretion, and a sustained T-cell effector response. Thus, the pleiotropic physiological functions of CD28 appear to be sustained by multiple downstream transcription factors that are yet to be fully defined. In this context, the CD28-deficient JF3 T-cell clone provides a novel convenient model to further dissect the CD28-specific functions and signaling pathway.
Recent studies have identified distal elements that mediate long-range cytokine gene regulation and have implicated chromatin reorganization of cytokine gene loci (1) . In a previous report (2), we have proposed that preassembled protein-DNA complexes in the proximal-enhancer region of the IL-2R␣ gene play a crucial role in the precommitment of T cells to express this gene. In line with this hypothesis, three weak DH sites were already detected within the distal 5Ј region in resting T cells. The constitutive CREB/ATF factors bound to the crucial CRE/TRE site of DH site 4 can recruit chromatin-remodeling machineries that locally decondense chromatin. After CD3-CD28 stimulation, activation of the transcriptionally competent locus by binding of inducible phospho-CREB and AP-1 factors probably resulted in the strongly increased sensitivity of the DH4 site, as suggested by the ChIP assays. Further experiments are required to determine whether a long-range cross talk over 9 kb might functionally associate the CREB/ATF and AP-1 transcription factors bound to CRE/TRE within PRRIV/ CD28rE and the long-term activated Rel/NF-B proteins in response to CD28 signal transduction pathway bound to the proximal B site within PRRI (2, 13) . Furthermore, the characterization for the first time of a cluster of four DH sites located between kb Ϫ4 to Ϫ9 relative to the major transcription initiation site in the human IL-2R␣ gene locus opens new perspectives to our understanding of the transcriptional regulation of this important immunoregulatory gene.
